| Line Item | 2025-02-01 | Y/Y |
|---|---|---|
| Revenue | $1.25B | +33.3% |
| Cost of Revenue | $298.3M | +20.8% |
| Gross Profit | $950.9M | +37.7% |
| R&D Expense | $299.7M | +15.9% |
| SG&A Expense | $234.6M | +20.3% |
| Operating Income | -$190.0M | +41.2% |
| Pre-tax Income | -$150.4M | +46.9% |
| Income Tax | $4.5M | +34.4% |
| Net Income | -$154.9M |
| Line Item | 2025-02-01 | Y/Y |
|---|---|---|
| Cash & Equivalents | $227.6M | +67.9% |
| Accounts Receivable | $234.0M | +44.6% |
| Inventory | $38.9M | +75.0% |
| Current Assets | $1.15B | +29.1% |
| Total Assets | $2.02B | +16.7% |
| Current Liabilities | $761.3M | +28.6% |
| Total Liabilities | $955.1M | +16.5% |
| Line Item | 2025-02-01 | Y/Y |
|---|---|---|
| Operating Cash Flow | $131.7M | +1214.3% |
| Capital Expenditures | $20.2M | +84.2% |
| Investing Cash Flow | -$66.6M | +15.3% |
| Financing Cash Flow | $27.1M | +29.1% |
| Free Cash Flow | $111.5M | +589.6% |
| +46.0% |
| EPS (Basic) | -$0.28 | +48.1% |
| EPS (Diluted) | -$0.28 | +48.1% |
| Stockholders' Equity |
| $1.07B |
| +16.8% |